



CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on March 5, 2004

April Reeves
April Reeves

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Y. Choo *et al.*

Application No.: 10/033,129

Filed: December 27, 2001

For: BINDING PROTEINS FOR
RECOGNITION OF DNA

Examiner: Terry A. McKelvey

Group Art Unit: 1636

Confirmation No.: 1808

TERMINAL DISCLAIMER UNDER 37 C.F.R. § 1.321(c)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. Gendaq, Ltd. (the Assignee) is the owner of the entire right, title and interest in the instant reissue application, by virtue of an Assignment recorded on October 29, 2002 at Reel 013427, Frame 0063.

2. The Assignee is also the owner of the entire right, title and interest in U.S. Patent No. 6,013,453 by virtue of an assignment recorded on October 29, 2002 at Reel 013417, Frame 0819.

3. The assignee hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-captioned reissue application Serial No. 10/033,129 which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154-156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,013,453.

Assignee further agrees that any patent granted on the above-captioned reissue application Serial No. 10/033,129 shall be enforceable only for and during such period that it and prior Patent No. 6,013,453 are commonly owned; this agreement to run with any patent granted on the above-captioned reissue application Serial No. 10/033,129 and to be binding upon the grantee, its successors or assigns.

4. In making this disclaimer, the Assignee does not disclaim the terminal part of any patent granted on the above-captioned reissue application Serial No. 10/033,129 that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154-156 and 173 of prior Patent No. 6,013,453, as presently shortened by any terminal disclaimer; in the event that it later (a) expires for failure to pay a maintenance fee, (b) is held unenforceable, (c) is found invalid by a court of competent jurisdiction, (d) is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, (e) has all claims cancelled by a reexamination certificate, (f) is reissued, or (g) is, in any manner, terminated prior to the expiration of its full statutory term.

5. The undersigned is empowered to act on behalf of the Assignee.

6. A certificate under 37 C.F.R. § 3.73(b) is attached.

7. A check in the amount of \$110.00 for a Terminal Disclaimer fee under 37 C.F.R. § 1.20(d) is included.

Respectfully submitted,

Date: March 5, 2004

By: 

Edward O. Lanphier II
Director

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Y. Choo, A. Klug & I. Sanchez-GarciaApplication No./Patent No.: 10/033,129 Filed/Issue Date: December 27, 2001Entitled: BINDING PROTEINS FOR RECOGNITION OF DNA

Gendaq, Ltd., a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %
in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:


1. From: Y. Choo, A. Klug & I. Sanchez-Garcia To: Medical Research Council
The document was recorded in the United States Patent and Trademark Office at
Reel 8816, Frame 0194, or for which a copy thereof is attached.
2. From: Medical Research Council To: Gendaq, Ltd.
The document was recorded in the United States Patent and Trademark Office at
Reel 010446, Frame 0156, or for which a copy thereof is attached.
3. From: Gendaq, Ltd. To: Sangamo BioSciences, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 012211, Frame 0005, or for which a copy thereof is attached.

☒ Additional documents in the chain of title are listed on a supplemental sheet.

- ☐ Copies of assignments or other documents in the chain of title are attached.
[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

March 5, 2004
Date
(510) 970-6000
Telephone number

Edward O. Lanphier II
Typed or printed name

Signature
Director
Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



STATEMENT UNDER 37 CFR § 3.73(b)

Page 2 of 2

Continuation of part B (Chain of Title):

4. From: Sangamo BioSciences, Inc. To: Gendag, Ltd.

The document was recorded in the United States Patent and Trademark Office at
Reel 013427, Frame 0063